Kezar Life Sciences Inc.(KZR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KZR Kezar Life Sciences Inc.

Trading 05-16 10:48:30 EDT

0.7607

-0.0116

-1.50%

High0.7838	Low0.7510	Vol142.27K
Open0.7700	D1 Closing0.7723	Amplitude4.25%
Mkt Cap55.38M	Tradable Cap39.92M	Total Shares72.80M
T/O108.89K	T/O Rate0.27%	Tradable Shares52.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"KZR","market":"US","secType":"STK","nameCN":"Kezar Life Sciences Inc.","latestPrice":0.7607,"timestamp":1715870892994,"preClose":0.7723,"halted":0,"volume":142265,"delay":0,"floatShares":52477083,"shares":72801359,"eps":-1.394341,"marketStatus":"Trading","change":-0.0116,"latestTime":"05-16 10:48:30 EDT","open":0.77,"high":0.7838,"low":0.751,"amount":108888.37906800001,"amplitude":0.042471,"askPrice":0.7614,"askSize":600,"bidPrice":0.76,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.394341,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1715889600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":0.7723,"postHourTrading":{"tag":"盘后","latestPrice":0.8109,"preClose":0.7723,"latestTime":"18:47 EDT","volume":6216,"amount":4877.5559,"timestamp":1715813256445},"volumeRatio":0.715586},"requestUrl":"/m/hq/s/KZR","defaultTab":"news","newsList":[{"id":"2435575777","title":"Kalamazoo Resources Issues New Employee Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2435575777","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435575777?lang=en_us&edition=fundamental","pubTime":"2024-05-15 08:57","pubTimestamp":1715734625,"startTime":"0","endTime":"0","summary":"Kalamazoo Resources Ltd. (AU:KZR) has released an update. Kalamazoo Resources Ltd. has announced the issuance of 1,950,000 unquoted options set to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-issues-new-employee-options?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-issues-new-employee-options?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434343198","title":"Buy Rating Affirmed for Kezar Life Sciences Amid Promising Clinical Trials and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2434343198","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434343198?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:45","pubTimestamp":1715337958,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences (KZR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju fro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-kezar-life-sciences-amid-promising-clinical-trials-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-kezar-life-sciences-amid-promising-clinical-trials-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434257460","title":"Kezar Life Sciences GAAP EPS of -$0.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2434257460","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434257460?lang=en_us&edition=fundamental","pubTime":"2024-05-10 05:29","pubTimestamp":1715290159,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences press release  (NASDAQ:KZR): Q1  GAAP EPS of -$0.30.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104260-kezar-life-sciences-gaap-eps-of--030","is_publish_highlight":false,"gpt_icon":0},{"id":"2434040038","title":"Kezar Life Sciences Q1 EPS $(0.30) Beats $(0.33) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434040038","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434040038?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:40","pubTimestamp":1715287207,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 3.23 percent increase over losses of $(0.31) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38745793/kezar-life-sciences-q1-eps-0-30-beats-0-33-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2434981042","title":"BRIEF-Kezar Life Sciences Q1 Net Income USD -21.658 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2434981042","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434981042?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:01","pubTimestamp":1715284905,"startTime":"0","endTime":"0","summary":"May 09 (Reuters) - Kezar Life Sciences Q1 operating expenses USD 23.711 million. * Q1 operating income USD -23.711 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434408647","title":"Kalamazoo Resources Highlights Investment Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2434408647","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434408647?lang=en_us&edition=fundamental","pubTime":"2024-05-09 08:08","pubTimestamp":1715213317,"startTime":"0","endTime":"0","summary":"Kalamazoo Resources Ltd. (AU:KZR) has released an update. Kalamazoo Resources Ltd. has released an investment presentation outlining its mineral pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-highlights-investment-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-highlights-investment-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433272410","title":"Kezar Life Sciences Inc    expected to post a loss of 33 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2433272410","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433272410?lang=en_us&edition=fundamental","pubTime":"2024-05-07 19:23","pubTimestamp":1715081017,"startTime":"0","endTime":"0","summary":"* Kezar Life Sciences Inc     is expected to show a rise in quarterly revenue when it reports  results on May 9 (estimated) for the period ending March 31 2024   * The South San Francisco California-b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433238139","title":"Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433238139","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433238139?lang=en_us&edition=fundamental","pubTime":"2024-05-07 04:05","pubTimestamp":1715025900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May 06, 2024----Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar’s common stock on May 1, 2024, the grant date of the awards. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635.The stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date. The options are subject to the terms ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FpkhB05SzYzeIzcpS5Z1Sg--~B/aD0zNjA7dz0xMTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e0580bcd90cabe72f29284f8977464f8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FpkhB05SzYzeIzcpS5Z1Sg--~B/aD0zNjA7dz0xMTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e0580bcd90cabe72f29284f8977464f8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kezar-announces-inducement-grants-under-200500068.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430123462","title":"Kalamazoo Resources Advances Lithium and Gold Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2430123462","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2430123462?lang=en_us&edition=fundamental","pubTime":"2024-04-26 14:27","pubTimestamp":1714112850,"startTime":"0","endTime":"0","summary":"Kalamazoo Resources Ltd. (AU:KZR) has released an update. Kalamazoo Resources Ltd. has successfully launched Kali Metals on the ASX, with the IPO r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-advances-lithium-and-gold-projects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-advances-lithium-and-gold-projects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2430212301","title":"Kalamazoo Resources Navigates Cash Flow Dynamics","url":"https://stock-news.laohu8.com/highlight/detail?id=2430212301","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2430212301?lang=en_us&edition=fundamental","pubTime":"2024-04-26 14:17","pubTimestamp":1714112256,"startTime":"0","endTime":"0","summary":"Kalamazoo Resources Ltd. (AU:KZR) has released an update. Kalamazoo Resources Limited reported a quarterly cash outflow from operating activities o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-navigates-cash-flow-dynamics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kalamazoo-resources-navigates-cash-flow-dynamics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426927285","title":"13 Best Penny Stocks to Buy According to Billionaire Ken Griffin","url":"https://stock-news.laohu8.com/highlight/detail?id=2426927285","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2426927285?lang=en_us&edition=fundamental","pubTime":"2024-04-09 05:38","pubTimestamp":1712612280,"startTime":"0","endTime":"0","summary":"In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to Billionaire Ken Griffin.The markets were off to an impressive start in 2024, driven by expectations that the US Federal Reserve will embark on interest rate cuts. However, data is now showing that inflation remains sticky and the labor market tight, causing new concerns regarding the Fed's possible path towards rate cuts. In this environment it makes sense to look towards masters of the money game.With a portfolio value of over $460 billion, Citadel Investment Group is one of Wall Street's most tracked hedge funds, consistently surpassing 25% annual returns since 2016. While the hedge fund operates several portfolio funds, its lead fund is Wellington, which invests in various asset classes and sectors as part of its diversification strategy.Griffin's impressive performance in the market has every","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/atqRiw.cWSbsDMFCXsa08g--~B/aD02MDA7dz00Njc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5e10b7d436d0889c610b18e545065be2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/atqRiw.cWSbsDMFCXsa08g--~B/aD02MDA7dz00Njc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5e10b7d436d0889c610b18e545065be2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/13-best-penny-stocks-buy-213800186.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426926802","title":"BRIEF-Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426926802","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2426926802?lang=en_us&edition=fundamental","pubTime":"2024-04-09 04:17","pubTimestamp":1712607476,"startTime":"0","endTime":"0","summary":"April 8 (Reuters) - Kezar Life Sciences Inc   :   * KEZAR ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422266009","title":"From Pennies to Fortunes: 3 Stocks Set to Make Millionaires","url":"https://stock-news.laohu8.com/highlight/detail?id=2422266009","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2422266009?lang=en_us&edition=fundamental","pubTime":"2024-03-28 04:30","pubTimestamp":1711571400,"startTime":"0","endTime":"0","summary":"Galiano Gold : Its record throughput and high recovery rates signify operational excellence.Aurora : The consistent commercial progress highlights market acceptance of autonomous trucking solutions.All leverage collaborations with other industry players to expand their market reach and accelerate product development.But the trip still needs to go on. Explorers see autonomous driving solutions emerging in the future as they focus on Aurora Innovation . The technology of the third one paves the path for the transportation revolution and redefines possibilities beyond the intergalactic roads of trade.Furthermore, Galiano Gold produced 31,947 ounces of gold in Q4. As seen by the134,077 ouncesproduced in 2023, this amount adds to the general trend of rising output. Finally, this year’s production surpassed the updated production projection’s 120,000–130,000-ounce upper limit. Overall, such a steady output increase shows the business’s operational expertise and ability to reach and exceed go","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/03/from-pennies-to-fortunes-3-stocks-set-to-make-millionaires/","is_publish_highlight":false,"gpt_icon":0},{"id":"2422056519","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422056519","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422056519?lang=en_us&edition=fundamental","pubTime":"2024-03-25 20:20","pubTimestamp":1711369253,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kezar Life Sciences (KZR – Research Report), Fisher & Paykel Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-kezar-life-sciences-kzr-fisher-paykel-healthcare-corporation-limited-otherfspkf-and-cue-health-hlth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-kezar-life-sciences-kzr-fisher-paykel-healthcare-corporation-limited-otherfspkf-and-cue-health-hlth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2421382789","title":"BRIEF-Kezar Life Sciences  Registering Offer And Sale Of Shares Of Common Stock Of Up To $24.8 Million From Time To Time Through TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2421382789","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2421382789?lang=en_us&edition=fundamental","pubTime":"2024-03-23 04:24","pubTimestamp":1711139078,"startTime":"0","endTime":"0","summary":"March 22 (Reuters) - Kezar Life Sciences Inc   :   * KEZAR LIFE SCIENCES INC -  REGISTERING OFFER AND SALE OF SHARES OF COMMON STOCK OF UP TO $24.8 MILLION FROM TIME TO TIME THROUGH TD COWENSource text for Eikon: [ID: Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419309769","title":"Kezar Life Sciences Inc reports results for the quarter ended in December - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2419309769","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2419309769?lang=en_us&edition=fundamental","pubTime":"2024-03-15 04:27","pubTimestamp":1710448020,"startTime":"0","endTime":"0","summary":"* Kezar Life Sciences Inc    reported a quarterly adjusted loss of 44 cents per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of -25 cen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419937301","title":"Kezar Life Sciences Q4 EPS $(0.44) Misses $(0.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2419937301","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2419937301?lang=en_us&edition=fundamental","pubTime":"2024-03-15 04:04","pubTimestamp":1710446651,"startTime":"0","endTime":"0","summary":"Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.38) by 15.79 percent. This is a 76 percent decrease over losses of $(0.25) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37716280/kezar-life-sciences-q4-eps-0-44-misses-0-38-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2419937580","title":"BRIEF-Kezar Life Sciences Q4 Operating Income USD -34.589 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2419937580","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2419937580?lang=en_us&edition=fundamental","pubTime":"2024-03-15 04:01","pubTimestamp":1710446505,"startTime":"0","endTime":"0","summary":"Mar 14 (Reuters) - Kezar Life Sciences Q4 operating expenses USD 34.589 million. * Q4 net income USD -32.26 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419693080","title":"Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2419693080","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2419693080?lang=en_us&edition=fundamental","pubTime":"2024-03-15 04:01","pubTimestamp":1710446460,"startTime":"0","endTime":"0","summary":"PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026. PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of topline data in mid-2025. KZR-261 dose escalation study currently enrolling ninth cohort; data update by year-end. Cash, cash equivalents and marketable securities totaled $201.4 million as of December 31, 2023. SOUTH SAN FRANCISCO, Calif., March 14, 2024----Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.PORTOLA – Phase 2a clinical trial of zetomipzomib in p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/s236_9a22wwnVHGBQlXYfg--~B/aD0zNjA7dz0xMTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f1365ae3f7c3e1607f7ea44d761645a9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/s236_9a22wwnVHGBQlXYfg--~B/aD0zNjA7dz0xMTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f1365ae3f7c3e1607f7ea44d761645a9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kezar-life-sciences-reports-fourth-200100733.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kezarlifesciences.com","stockEarnings":[{"period":"1week","weight":-0.0593},{"period":"1month","weight":-0.046},{"period":"3month","weight":-0.0841},{"period":"6month","weight":-0.1019},{"period":"1year","weight":-0.7468},{"period":"ytd","weight":-0.1848}],"compareEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":0.0502},{"period":"3month","weight":0.0553},{"period":"6month","weight":0.1752},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.1146}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.101182},{"month":2,"riseRate":0.833333,"avgChangeRate":0.110013},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.094959},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.079081},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.166052},{"month":6,"riseRate":0.4,"avgChangeRate":0.073665},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.081807},{"month":8,"riseRate":0.666667,"avgChangeRate":0.008901},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003986},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.065252},{"month":11,"riseRate":0.833333,"avgChangeRate":0.203618},{"month":12,"riseRate":0.5,"avgChangeRate":0.060618}],"exchange":"NASDAQ","name":"Kezar Life Sciences Inc.","nameEN":"Kezar Life Sciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kezar Life Sciences Inc.(KZR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kezar Life Sciences Inc.(KZR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kezar Life Sciences Inc.,KZR,Kezar Life Sciences Inc.股票,Kezar Life Sciences Inc.股票老虎,Kezar Life Sciences Inc.股票老虎国际,Kezar Life Sciences Inc.行情,Kezar Life Sciences Inc.股票行情,Kezar Life Sciences Inc.股价,Kezar Life Sciences Inc.股市,Kezar Life Sciences Inc.股票价格,Kezar Life Sciences Inc.股票交易,Kezar Life Sciences Inc.股票购买,Kezar Life Sciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kezar Life Sciences Inc.(KZR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kezar Life Sciences Inc.(KZR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}